Literature DB >> 22149658

The use of newer antiepileptic drugs in patients with renal failure.

Anyzeila Diaz1, Beverly Deliz, Selim R Benbadis.   

Abstract

Seizures and chronic kidney disease are both common and often coexist. Treating seizures in patients with renal failure, including those on dialysis, is a challenge that is frequently encountered, especially in the inpatient setting. For the newer antiepileptic drugs, there are limited data available, so an understanding of how each drug is affected by kidney disease and dialysis is critical in order to make rational choices qualitatively (which drug) and quantitatively (dosing). Generally, newer (second-generation) antiepileptic drugs are associated with fewer systemic side effects and drug-drug interactions, so they tend to be preferred in this population. The landscape of antiepileptic drugs is constantly evolving, with new compounds being released on a regular basis. Thus, several new agents have become available since the last review of this topic (in 2006) and these are the ones discussed here. Most require dosage adjustment according to the degree of renal failure, and most require extra doses after dialysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22149658     DOI: 10.1586/ern.11.181

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

1.  Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide.

Authors:  Willi Cawello; Uwe Fuhr; Ursula Hering; Haidar Maatouk; Atef Halabi
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 2.  Managing Antiepileptic Medication in Dialysis Patients.

Authors:  Karla Alejandra Mora Rodríguez; Selim R Benbadis
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

3.  A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient.

Authors:  Svenja K Bahte; Marcus Hiss; Ralf Lichtinghagen; Jan T Kielstein
Journal:  BMC Nephrol       Date:  2014-04-16       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.